Search research articles
Contact Us
Filters
Showing results (741-750 of 758) with videos related to
Page
of 76
Sort By:
The Lancet Regional Health. Western Pacific
|
September 11, 2023
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort
Nicholas W S Chew, Bryan Chong, Si Min Kuo, et al.
Cell Reports
|
July 24, 2025
Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules
Robert C Wells, Padma Akkapeddi, Darren Chan, et al.
Annals of Intensive Care
|
January 29, 2021
Current use of inotropes in circulatory shock
Thomas W L Scheeren, Jan Bakker, Thomas Kaufmann, et al.
Acta Anaesthesiologica Scandinavica
|
February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan
M W Munch, Anders Granholm, S N Myatra, et al.
Journal of the American College of Cardiology
|
September 20, 2023
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review
Gemma A Figtree, Stephen T Vernon, Jason A Harmer, et al.
Acta Anaesthesiologica Scandinavica
|
February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis
Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Science Translational Medicine
|
August 14, 2024
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Scarlett J Barker, Mai B Thayer, Chaeyoung Kim, et al.
Burns : Journal of the International Society for Burn Injuries
|
October 15, 2023
Surviving Sepsis After Burn Campaign
David G Greenhalgh, David M Hill, David M Burmeister, et al.
Intensive Care Medicine
|
November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine
|
April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Anders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Page
of 76
Search research articles
Search
Showing results (741-750 of 758) with videos related to
Sort By:
Page
of 76
The Lancet Regional Health. Western Pacific
|
September 11, 2023
Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort
Nicholas W S Chew, Bryan Chong, Si Min Kuo, et al.
Cell Reports
|
July 24, 2025
Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules
Robert C Wells, Padma Akkapeddi, Darren Chan, et al.
Annals of Intensive Care
|
January 29, 2021
Current use of inotropes in circulatory shock
Thomas W L Scheeren, Jan Bakker, Thomas Kaufmann, et al.
Acta Anaesthesiologica Scandinavica
|
February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan
M W Munch, Anders Granholm, S N Myatra, et al.
Journal of the American College of Cardiology
|
September 20, 2023
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review
Gemma A Figtree, Stephen T Vernon, Jason A Harmer, et al.
Acta Anaesthesiologica Scandinavica
|
February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis
Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Science Translational Medicine
|
August 14, 2024
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Scarlett J Barker, Mai B Thayer, Chaeyoung Kim, et al.
Burns : Journal of the International Society for Burn Injuries
|
October 15, 2023
Surviving Sepsis After Burn Campaign
David G Greenhalgh, David M Hill, David M Burmeister, et al.
Intensive Care Medicine
|
November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine
|
April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Anders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Page
of 76